Glenmark Pharmaceuticals, a well-known Indian pharma company, is in the news for its strong performance in the stock market. Many experts believe that its share price may grow by 8% to 10% this September, which is good news for investors.
Current Market Status
Share Price: Around ₹2,060 (as of September 8, 2025)
Recent Trend: Up nearly 30% in the last 3 months
52-Week Range: Lowest ~₹1,275 and Highest ~₹2,284
This shows that Glenmark has been gaining strength in recent months.
Why Experts Are Positive https://infinityxverse.com/breaking-news-update-top-stories-shaping-america-this-wee/
1. AbbVie Deal
Glenmark signed a $700 million licensing deal with global pharma giant AbbVie.
This gives the company a strong push in research and new medicine development.
After the deal, Glenmark’s share jumped by almost 14% in a single day.
2. FDA Approvals
Its Monroe plant in the US recently got FDA clearance.
Approval of its respiratory drug (generic version of Flovent) is expected soon.
This opens the door for better US sales.
3. Analysts’ Targets
HSBC: Target price ₹2,380
Motilal Oswal: Target price ₹2,430
Some analysts even see it reaching ₹2,800
These levels are higher than the current price, showing clear growth potential.
Risks to Watch
Quarterly Profits: In Q1, Glenmark’s profit fell 9% due to price pressure in US and Europe.
ICICI Securities gave a cautious view with a target of only ₹1,300.
If earnings continue to slow, the stock may face resistance.
What 8–10% Growth Means
Current Price: ~₹2,060
+8% → ₹2,225
+10% → ₹2,266
These levels are very much possible in September if positive news keeps coming.
Impact on Indian Investors & Options Market
If Glenmark rises 8–10%, it will boost confidence in the pharma sector overall.
Traders in futures & options (F&O) can use:
Long Call Options to benefit from price rise.
Bull Call Spreads for moderate but safe profit.
Covered Calls for those already holding shares.
Conclusion
For Indian investors, Glenmark looks promising this September. With the AbbVie deal, FDA approvals, and strong analyst targets, an 8–10% rise is possible in the short term. However, profit pressure in global markets remains a risk
